A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients.
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Lenalidomide (Primary) ; Prednisone (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 10 Dec 2019 Status changed from active, no longer recruiting to completed.
- 23 Jul 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 15 Jun 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.